| Year |
Citation |
Score |
| 2002 |
Hsu BL, Harless SM, Lindsley RC, Hilbert DM, Cancro MP. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. Journal of Immunology (Baltimore, Md. : 1950). 168: 5993-6. PMID 12055205 DOI: 10.4049/Jimmunol.168.12.5993 |
0.558 |
|
| 2001 |
Harless SM, Lentz VM, Sah AP, Hsu BL, Clise-Dwyer K, Hilbert DM, Hayes CE, Cancro MP. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Current Biology : Cb. 11: 1986-9. PMID 11747827 DOI: 10.1016/S0960-9822(01)00598-X |
0.408 |
|
| 1996 |
Vidal K, Hsu BL, Williams CB, Allen PM. Endogenous altered peptide ligands can affect peripheral T cell responses. The Journal of Experimental Medicine. 183: 1311-21. PMID 8666889 DOI: 10.1084/jem.183.4.1311 |
0.34 |
|
| 1995 |
Hsu BL, Evavold BD, Allen PM. Modulation of T cell development by an endogenous altered peptide ligand. The Journal of Experimental Medicine. 181: 805-10. PMID 7836933 DOI: 10.1084/Jem.181.2.805 |
0.325 |
|
| 1991 |
Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. Journal of Neuroscience Research. 28: 254-60. PMID 2033653 DOI: 10.1002/jnr.490280213 |
0.347 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 1988 |
Celander D, Hsu BL, Haseltine WA. Regulatory elements within the murine leukemia virus enhancer regions mediate glucocorticoid responsiveness. Journal of Virology. 62: 1314-22. PMID 2831392 DOI: 10.1128/jvi.62.4.1314-1322.1988 |
0.233 |
|
| 2007 |
Baxter LL, Hsu BJ, Umayam L, Wolfsberg TG, Larson DM, Frith MC, Kawai J, Hayashizaki Y, Carninci P, Pavan WJ. Informatic and genomic analysis of melanocyte cDNA libraries as a resource for the study of melanocyte development and function. Pigment Cell Research / Sponsored by the European Society For Pigment Cell Research and the International Pigment Cell Society. 20: 201-9. PMID 17516927 DOI: 10.1111/J.1600-0749.2007.00372.X |
0.189 |
|
| 2011 |
Vastesaeger N, van der Heijde D, Inman RD, Wang Y, Deodhar A, Hsu B, Rahman MU, Dijkmans B, Geusens P, Vander Cruyssen B, Collantes E, Sieper J, Braun J. Predicting the outcome of ankylosing spondylitis therapy. Annals of the Rheumatic Diseases. 70: 973-81. PMID 21402563 DOI: 10.1136/Ard.2010.147744 |
0.101 |
|
| 2018 |
Xu Y, Hu C, Zhuang Y, Hsu B, Xu Z, Zhou H. Confirmatory Population Pharmacokinetic Analysis for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin-6, in Patients With Moderately to Severely Active Rheumatoid Arthritis. Journal of Clinical Pharmacology. PMID 29578578 DOI: 10.1002/jcph.1101 |
0.09 |
|
| 1988 |
Reddy AP, Hsu BL, Reddy PS, Li NQ, Thyagaraju K, Reddy CC, Tam MF, Tu CP. Expression of glutathione peroxidase I gene in selenium-deficient rats. Nucleic Acids Research. 16: 5557-68. PMID 2838821 DOI: 10.1093/nar/16.12.5557 |
0.083 |
|
| 2019 |
Sweet K, Dasgupta B, de Vries D, Gourley I, Hsu B, Loza MJ, Taylor PC. Sirukumab and adalimumab reduce power Doppler ultrasound signal in patients with rheumatoid arthritis by 4 weeks in a phase III trial. Annals of the Rheumatic Diseases. PMID 31018960 DOI: 10.1136/annrheumdis-2019-215183 |
0.069 |
|
| 2018 |
Hu C, Xu Y, Zhuang Y, Hsu B, Sharma A, Xu Z, Zhang L, Zhou H. Joint longitudinal model development: application to exposure-response modeling of ACR and DAS scores in rheumatoid arthritis patients treated with sirukumab. Journal of Pharmacokinetics and Pharmacodynamics. PMID 29961161 DOI: 10.1007/s10928-018-9598-5 |
0.062 |
|
| 2018 |
Tanaka Y, Takeuchi T, Harigai M, Yamanaka H, Nakano T, Akagi K, Ukyo Y, Hsu B. Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, double-blind, multicenter, phase 3 study (SIRROUND-T). Modern Rheumatology. 1-19. PMID 29532734 DOI: 10.1080/14397595.2018.1452345 |
0.062 |
|
| 2005 |
Hsu B, Cass L, Williams WV. Application of transcriptome analysis to clinical pharmacology studies Current Molecular Medicine. 5: 65-82. PMID 15720271 DOI: 10.2174/1566524053152889 |
0.06 |
|
| 2017 |
Takeuchi T, Thorne C, Karpouzas G, Sheng S, Xu W, Rao R, Fei K, Hsu B, Tak PP. Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study. Annals of the Rheumatic Diseases. PMID 28855173 DOI: 10.1136/annrheumdis-2017-211328 |
0.059 |
|
| 2012 |
Wagner C, Visvanathan S, Braun J, van der Heijde D, Deodhar A, Hsu B, Mack M, Elashoff M, Inman RD. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Annals of the Rheumatic Diseases. 71: 674-80. PMID 22039165 DOI: 10.1136/Ard.2010.148890 |
0.058 |
|
| 2014 |
van der Heijde D, Deodhar A, Braun J, Mack M, Hsu B, Gathany TA, Inman RD, Han C. The effect of golimumab therapy on disease activity and health-related quality of life in patients with ankylosing spondylitis: 2-year results of the GO-RAISE trial. The Journal of Rheumatology. 41: 1095-103. PMID 24737912 DOI: 10.3899/Jrheum.131003 |
0.052 |
|
| 2018 |
Xu Y, Hu C, Zhuang Y, Hsu B, Xu Z, Sharma A, Zhou H. Exposure-Response Modeling Analyses for Sirukumab, a Human Monoclonal Antibody Targeting Interleukin 6, in Patients With Moderately to Severely Active Rheumatoid Arthritis. Journal of Clinical Pharmacology. PMID 29901815 DOI: 10.1002/jcph.1272 |
0.048 |
|
| 2020 |
Hsu B, Sherina V, McCall MN. Auto-regressive modeling and diagnostics for qPCR amplification. Bioinformatics (Oxford, England). PMID 33244594 DOI: 10.1093/bioinformatics/btaa1000 |
0.048 |
|
| 2017 |
Sun Y, Wang D, Salvadore G, Hsu B, Curran M, Casper C, Vermeulen J, Kent JM, Singh J, Drevets WC, Wittenberg GM, Chen G. The effects of interleukin-6 neutralizing antibodies on symptoms of depressed mood and anhedonia in patients with rheumatoid arthritis and multicentric Castleman's disease. Brain, Behavior, and Immunity. PMID 28676350 DOI: 10.1016/j.bbi.2017.06.014 |
0.047 |
|
| 2021 |
Aletaha D, Bingham CO, Karpouzas GA, Takeuchi T, Thorne C, Bili A, Agarwal P, Hsu B, Rao R, Brown K, Tanaka Y. Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). Rmd Open. 7. PMID 33526709 DOI: 10.1136/rmdopen-2020-001465 |
0.046 |
|
| 2014 |
Braun J, Baraliakos X, Hermann KG, Deodhar A, van der Heijde D, Inman R, Beutler A, Zhou Y, Xu S, Hsu B. The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Annals of the Rheumatic Diseases. 73: 1107-13. PMID 23644549 DOI: 10.1136/Annrheumdis-2012-203075 |
0.044 |
|
| 2018 |
Takeuchi T, Tanaka Y, Yamanaka H, Harigai M, Nakano T, Akagi K, Ukyo Y, Hsu B. Efficacy and safety of sirukumab in Japanese patients with moderate to severe rheumatoid arthritis inadequately controlled by disease modifying anti-rheumatic drugs: Subgroup analysis of a phase 3 study. Modern Rheumatology. 1-23. PMID 29336187 DOI: 10.1080/14397595.2018.1428929 |
0.041 |
|
| 2016 |
Zhou AJ, Lee Y, Salvadore G, Hsu B, Fonseka TM, Kennedy SH, McIntyre RS. Sirukumab: A Potential Treatment for Mood Disorders? Advances in Therapy. PMID 27913990 DOI: 10.1007/S12325-016-0455-X |
0.041 |
|
| 2013 |
van der Heijde D, Braun J, Deodhar A, Inman RD, Xu S, Mack ME, Hsu B. Comparison of three enthesitis indices in a multicentre, randomized, placebo-controlled trial of golimumab in ankylosing spondylitis (GO-RAISE). Rheumatology (Oxford, England). 52: 321-5. PMID 23024015 DOI: 10.1093/Rheumatology/Kes251 |
0.04 |
|
| 2015 |
Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Annals of the Rheumatic Diseases. 74: 538-46. PMID 24344160 DOI: 10.1136/annrheumdis-2013-204195 |
0.039 |
|
| 2018 |
Takeuchi T, Yamanaka H, Harigai M, Tamamura R, Kato Y, Ukyo Y, Nakano T, Hsu B, Tanaka Y. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients. Arthritis Research & Therapy. 20: 42. PMID 29514712 DOI: 10.1186/s13075-018-1536-9 |
0.039 |
|
| 2012 |
van der Heijde D, Machado P, Braun J, Hermann KG, Baraliakos X, Hsu B, Baker D, Landewé R. MRI inflammation at the vertebral unit only marginally predicts new syndesmophyte formation: a multilevel analysis in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 71: 369-73. PMID 21979001 DOI: 10.1136/annrheumdis-2011-200208 |
0.035 |
|
| 2012 |
Braun J, Deodhar A, Inman RD, van der Heijde D, Mack M, Xu S, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Annals of the Rheumatic Diseases. 71: 661-7. PMID 22012970 DOI: 10.1136/Ard.2011.154799 |
0.035 |
|
| 2013 |
Machado P, Landewé R, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D. Ankylosing spondylitis patients with and without psoriasis do not differ in disease phenotype. Annals of the Rheumatic Diseases. 72: 1104-7. PMID 23667171 DOI: 10.1136/annrheumdis-2012-202922 |
0.035 |
|
| 2018 |
Thorne C, Takeuchi T, Karpouzas GA, Sheng S, Kurrasch R, Fei K, Hsu B. Investigating sirukumab for rheumatoid arthritis: 2-year results from the phase III SIRROUND-D study. Rmd Open. 4: e000731. PMID 30564449 DOI: 10.1136/rmdopen-2018-000731 |
0.035 |
|
| 2016 |
Inman RD, Baraliakos X, Hermann KA, Braun J, Deodhar A, van der Heijde D, Xu S, Hsu B. Serum biomarkers and changes in clinical/MRI evidence of golimumab-treated patients with ankylosing spondylitis: results of the randomized, placebo-controlled GO-RAISE study. Arthritis Research & Therapy. 18: 304. PMID 28031053 DOI: 10.1186/S13075-016-1200-1 |
0.034 |
|
| 2018 |
Taylor PC, Schiff MH, Wang Q, Jiang Y, Zhuang Y, Kurrasch R, Daga S, Rao R, Tak PP, Hsu B. Efficacy and safety of monotherapy with sirukumab compared with adalimumab monotherapy in biologic-naïve patients with active rheumatoid arthritis (SIRROUND-H): a randomised, double-blind, parallel-group, multinational, 52-week, phase 3 study. Annals of the Rheumatic Diseases. PMID 29483080 DOI: 10.1136/annrheumdis-2017-212496 |
0.032 |
|
| 2008 |
Inman RD, Davis JC, Heijde Dv, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis and Rheumatism. 58: 3402-12. PMID 18975305 DOI: 10.1002/Art.23969 |
0.032 |
|
| 2016 |
Braun J, Baraliakos X, Hermann KA, Xu S, Hsu B. Serum C-reactive Protein Levels Demonstrate Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with Golimumab. The Journal of Rheumatology. PMID 27422890 DOI: 10.3899/jrheum.160003 |
0.031 |
|
| 2012 |
Braun J, Baraliakos X, Hermann KG, van der Heijde D, Inman RD, Deodhar AA, Baratelle A, Xu S, Xu W, Hsu B. Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Annals of the Rheumatic Diseases. 71: 878-84. PMID 22128083 DOI: 10.1136/Annrheumdis-2011-200308 |
0.031 |
|
| 2019 |
Wittenberg GM, Stylianou A, Zhang Y, Sun Y, Gupta A, Jagannatha PS, Wang D, Hsu B, Curran ME, Khan S, Chen G, Bullmore ET, Drevets WC. Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders. Molecular Psychiatry. PMID 31427751 DOI: 10.1038/s41380-019-0471-8 |
0.03 |
|
| 2010 |
Metter RB, Ifkovits JL, Hou K, Vincent L, Hsu B, Wang L, Mauck RL, Burdick JA. Biodegradable fibrous scaffolds with diverse properties by electrospinning candidates from a combinatorial macromer library. Acta Biomaterialia. 6: 1219-26. PMID 19853066 DOI: 10.1016/J.Actbio.2009.10.027 |
0.029 |
|
| 2012 |
Machado P, Landewé RB, Braun J, Baraliakos X, Hermann KG, Hsu B, Baker D, van der Heijde D. MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor. Annals of the Rheumatic Diseases. 71: 2002-5. PMID 22915615 DOI: 10.1136/annrheumdis-2012-201999 |
0.029 |
|
| 2013 |
Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis. Rheumatology (Oxford, England). 52: 1845-55. PMID 23838027 DOI: 10.1093/Rheumatology/Ket233 |
0.028 |
|
| 2016 |
Braun J, Baraliakos X, Hermann KA, Xu S, Hsu B. Serum Vascular Endothelial Growth Factor Levels Lack Predictive Value in Patients with Active Ankylosing Spondylitis Treated with Golimumab. The Journal of Rheumatology. PMID 26932345 DOI: 10.3899/jrheum.150897 |
0.027 |
|
| 2016 |
Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis. The Journal of Rheumatology. PMID 27803138 DOI: 10.3899/jrheum.160420 |
0.026 |
|
| 2015 |
Deodhar A, Braun J, Inman RD, van der Heijde D, Zhou Y, Xu S, Han C, Hsu B. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study. Annals of the Rheumatic Diseases. 74: 757-61. PMID 25387477 DOI: 10.1136/Annrheumdis-2014-205862 |
0.026 |
|
| 2010 |
Robinson D, Aguilar D, Schoenwetter M, Dubois R, Russak S, Ramsey-Goldman R, Navarra S, Hsu B, Revicki D, Cella D, Rapaport MH, Renahan K, Ress R, Wallace D, Weisman M. Impact of systemic lupus erythematosus on health, family, and work: the patient perspective. Arthritis Care & Research. 62: 266-73. PMID 20191527 DOI: 10.1002/acr.20077 |
0.024 |
|
| 2014 |
Smolen JS, Weinblatt ME, Sheng S, Zhuang Y, Hsu B. Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy. Annals of the Rheumatic Diseases. 73: 1616-25. PMID 24699939 DOI: 10.1136/annrheumdis-2013-205137 |
0.024 |
|
| 2010 |
Deodhar A, Braun J, Inman RD, Mack M, Parasuraman S, Buchanan J, Hsu B, Gathany T, van der Heijde D. Golimumab reduces sleep disturbance in patients with active ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Care & Research. 62: 1266-71. PMID 20506403 DOI: 10.1002/Acr.20233 |
0.024 |
|
| 2013 |
Szepietowski JC, Nilganuwong S, Wozniacka A, Kuhn A, Nyberg F, van Vollenhoven RF, Bengtsson AA, Reich A, de Vries DE, van Hartingsveldt B, Robinson DW, Gordon R, Hsu B. Phase I, randomized, double-blind, placebo-controlled, multiple intravenous, dose-ascending study of sirukumab in cutaneous or systemic lupus erythematosus. Arthritis and Rheumatism. 65: 2661-71. PMID 23896980 DOI: 10.1002/art.38091 |
0.022 |
|
| 2003 |
Banerjee-Basu S, Moreland T, Hsu BJ, Trout KL, Baxevanis AD. The Homeodomain Resource: 2003 update. Nucleic Acids Research. 31: 304-6. PMID 12520008 |
0.021 |
|
| 2006 |
Mariño-Ramírez L, Hsu B, Baxevanis AD, Landsman D. The Histone Database: a comprehensive resource for histones and histone fold-containing proteins. Proteins. 62: 838-42. PMID 16345076 DOI: 10.1002/Prot.20814 |
0.018 |
|
| 2018 |
van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet (London, England). PMID 30249507 DOI: 10.1016/S0140-6736(18)32167-6 |
0.015 |
|
| 2003 |
Nalbant S, Corominas H, Hsu B, Chen LX, Schumacher HR, Kitumnuaypong T. Ultrasonography for assessment of subcutaneous nodules. The Journal of Rheumatology. 30: 1191-5. PMID 12784388 |
0.013 |
|
| 2016 |
Rovin B, van Vollenhoven R, Aranow C, Wagner C, Gordon R, Zhuang Y, Belkowski S, Hsu B. A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of treatment with sirukumab (CNTO 136) in patients with active lupus nephritis. Arthritis & Rheumatology (Hoboken, N.J.). PMID 27110697 DOI: 10.1002/art.39722 |
0.012 |
|
| 2013 |
Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, Xu S, Rahman MU. Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials Arthritis Care and Research. 65: 309-313. PMID 22782640 DOI: 10.1002/acr.21788 |
0.01 |
|
| 2012 |
Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, Beutler A, Doyle MK, Hsu B, Rahman MU. Interferon-γ release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis and Rheumatism. 64: 2068-77. PMID 22238071 DOI: 10.1002/Art.34382 |
0.01 |
|
| Hide low-probability matches. |